Search results
Showing 1 to 9 of 9 results for risdiplam
Nusinersen and risdiplam for treating spinal muscular atrophy (TA1162)
Evidence-based recommendations on nusinersen (Spinraza) and risdiplam (Evrysdi) for treating spinal muscular atrophy.
In development Reference number: GID-TA11733 Expected publication date: 26 August 2026
Our forward view highlights the areas we will prioritise in the coming year.
This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families
People living with spinal muscular atrophy (SMA) in England are set to gain routine access to two potentially life-changing treatments, following our publication of final draft guidance today.
This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)
Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.
Risdiplam not recommend for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).